Reversible Systolic Heart Failure in a Patient on Ibrutinib Chemotherapy

Ibrutinib is an irreversible Bruton tyrosine kinase inhibitor that is approved for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, and mantle cell lymphoma. However, it is associated with signific...

Descripción completa

Detalles Bibliográficos
Autores principales: Khaja, Misbahuddin, Gurjar, Hitesh, Yapor, Laura, Abraham, Minu C, Hernandez, Nolberto, Haider, Asim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013282/
https://www.ncbi.nlm.nih.gov/pubmed/35449638
http://dx.doi.org/10.7759/cureus.23266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013282/
https://www.ncbi.nlm.nih.gov/pubmed/35449638
http://dx.doi.org/10.7759/cureus.23266

Ejemplares similares